Metallothioneins are multipurpose neuroprotectants during brain pathology
Open accessThe DOI matches its Crossref record.
Abstract
Metallothioneins (MTs) constitute a family of cysteine‐rich metalloproteins involved in cytoprotection during pathology. In mammals there are four isoforms (MT‐I − IV), of which MT‐I and ‐II (MT‐I + II) are the best characterized MT proteins in the brain. Accumulating studies have demonstrated MT‐I + II as multipurpose factors important for host defense responses, immunoregulation, cell survival and brain repair. This review will focus on expression and roles of MT‐I + II in the disordered brain. Initially, studies of genetically modified mice with MT‐I + II deficiency or endogenous MT‐I overexpression demonstrated the importance of MT‐I + II for coping with brain pathology. In addition, exogenous MT‐I or MT‐II injected intraperitoneally is able to promote similar effects as those of endogenous MT‐I + II, which indicates that MT‐I + II have both extra‐ and intracellular actions. In injured brain, MT‐I + II inhibit macrophages, T lymphocytes and their formation of interleukins, tumor necrosis factor‐α, matrix metalloproteinases, and reactive oxygen species. In addition, MT‐I + II enhance cell cycle progression, mitosis and cell survival, while neuronal apoptosis is inhibited. The precise mechanisms downstream of MT‐I + II have not been fully established, but convincing data show that MT‐I + II are essential for coping with neuropathology and for brain recovery. As MT‐I and/or MT‐II compounds are well tolerated, they may provide a potential therapy for a range of brain disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Critical Role of Zinc as Either an Antioxidant or a Prooxidant in Cellular Systems
Lee, S. R. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/9156285 · Cited by 458
“Moreover, the inherent activity of MT as an antioxidant may be involved in the protection against oxidative damage, such as radiation injury [66] or central nervous system pathology [67].”
BackgroundThe roles of metallothioneins in carcinogenesis
Si, M., & Lang, J. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0645-x · Cited by 454
Li, L., Acioglu, C., Heary, R. F., & Elkabes, S. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.10.007 · Cited by 283
“tein), SLC1A2 (solute carrier family 1 member 2; excitatory amino acid transporter 2) and MTs (metallothioneins) (Penkowa, 2006), astrocytes”
Neuron-Astrocyte Interactions in Parkinson’s Disease
Miyazaki, I., & Asanuma, M. (2020) · Cells · doi:10.3390/cells9122623 · Cited by 186
“The two abundant isoforms, MT-1 and -2 (MT-1/-2), are expressed in most organs including the brain [60].”
BackgroundInfluentialNeuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo
Lanza, C., Morando, S., Voci, A., Canesi, L., Principato, M. C., Serpero, L. D., Mancardi, G., Uccelli, A., & Vergani, L. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06268.x · Cited by 175
“MTs may also act as anti-inflammatory molecules that reduce activation and cerebral recruitment of monocytes/macrophages and T-cells, and counter activation of microglia and immune cells (Penkowa 2006).”
Background
Metadata
- Authors
- Penkowa, M.
- Venue
- The FEBS Journal
- Publisher
- Wiley
- Published
- 2006-04-05
- Volume
- 273
- Issue
- 9
- Pages
- 1857-1870
- ISSN
- 1742-464X (ISSN-L)
- 1742-4658
- OpenAlex
- W1567272218
- Cited by
- 131
- References
- 0
- FWCI
- 13.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metallothioneins are multipurpose neuroprotectants during brain pathology. https://app.cochat.ai/papers/10.1111/j.1742-4658.2006.05207.x
- The paper
- Penkowa, M. (2006). Metallothioneins are multipurpose neuroprotectants during brain pathology. The FEBS Journal. https://doi.org/10.1111/j.1742-4658.2006.05207.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.